March 6, 2026

AMN Healthcare Services Inc (AMN): Investor Outlook with a Focus on Strategic Growth Amidst Market Challenges

AMN Healthcare Services Inc (NYSE: AMN), a prominent player in the healthcare sector, is navigating a complex landscape with its technology-enabled workforce solutions. Headquartered in Dallas, Texas, AMN has carved..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenging Terrain with a Potential 46.20% Upside

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) stands at the intersection of innovation and uncertainty within the biotechnology landscape. Specializing in cell engineering and biosecurity, the Boston-based company is forging pathways..

Sionna Therapeutics, Inc. (SION) Stock Analysis: A 42% Potential Upside in the Biotech Sector

Sionna Therapeutics, Inc. (NASDAQ: SION), a burgeoning name in the biotechnology sector, is capturing investor attention with a significant potential upside of 42.10%. Specializing in the development of treatments for..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Promising Upside with a 166% Growth Potential

Niagen Bioscience, Inc. (NASDAQ: NAGE) is emerging as a noteworthy player in the biotechnology sector, specifically within the healthcare industry. With its focus on developing innovative healthy aging products, Niagen..

Tilray Brands, Inc. (TLRY) Stock Analysis: Unpacking a Potential 66% Upside for Investors

Tilray Brands, Inc. (NASDAQ: TLRY) stands out in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. This Canadian-based company has been navigating the evolving landscape of..

GH Research PLC (GHRS) Stock Analysis: A Biotech Contender with 151% Potential Upside

For investors scanning the volatile biotech sector, GH Research PLC (NASDAQ: GHRS) offers a compelling proposition. This Dublin-based clinical-stage biopharmaceutical company, currently valued at $940.99 million, is making significant strides..

Syndax Pharmaceuticals (SNDX) Stock Analysis: A Biotech with 76.51% Upside Potential

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is drawing significant attention from investors, thanks to its impressive potential upside and robust pipeline in the biotechnology sector. With a market capitalization of $1.9..

Neuropace, Inc. (NPCE) Stock Analysis: Exploring a 46% Upside Potential Amid Robust Revenue Growth

For investors with an eye on the healthcare sector, Neuropace, Inc. (NASDAQ: NPCE) presents a compelling opportunity, particularly given its potential upside of 46.14% based on analyst target prices. This..

Sonida Senior Living, Inc. (SNDA): A Senior Care Innovator with Revenue Growth but Facing Market Challenges

Sonida Senior Living, Inc. (SNDA) stands as a notable player in the healthcare sector, particularly within the medical care facilities industry. With a market capitalization of $680.59 million, the company..

OrthoPediatrics Corp. (KIDS) Investor Outlook: A 39.67% Potential Upside Amid Strong Buy Ratings

OrthoPediatrics Corp. (NASDAQ: KIDS), a leader in pediatric orthopedic solutions, is capturing investor attention with its innovative product lineup and a compelling market position in the healthcare sector. Specializing in..

Precigen, Inc. (PGEN): Analyst Ratings Reveal a Potential 152% Upside for Biotech Innovator

Precigen, Inc. (NASDAQ: PGEN), a cutting-edge biopharmaceutical company, has garnered significant attention from investors due to its promising prospects in the biotechnology sector. With a current market capitalization of $1.19..

Upstream Bio, Inc. (UPB) Stock Analysis: Potential 524% Upside Beckons Investors Amid Phase 2 Developments

Upstream Bio, Inc. (UPB), a promising player in the biotechnology sector, is garnering attention with its notable potential for substantial stock appreciation. As a clinical-stage biotechnology company based in Waltham,..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Biotech Gem with a 43% Upside Potential

Tyra Biosciences, Inc. (NASDAQ: TYRA) has captured the attention of investors with its promising pipeline and significant upside potential. As a clinical-stage biotechnology company, Tyra is at the forefront of..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 73.77% Potential Upside

Castle Biosciences, Inc. (NASDAQ: CSTL) is making waves in the healthcare sector, particularly in the diagnostics and research industry. Headquartered in Friendswood, Texas, this molecular diagnostics company has carved out..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Eyeing a 96.75% Potential Upside in Biotechnology

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company, stands at the forefront of developing innovative cell and exosome-based therapeutics. With its focus on addressing unmet medical needs, particularly in..

Verastem, Inc. (VSTM) Stock Analysis: Exploring a 169% Potential Upside Amidst Promising Cancer Therapies

Verastem, Inc. (NASDAQ: VSTM), a biotechnology company based in Needham, Massachusetts, has caught the eye of investors with its ambitious ventures in the healthcare sector. Specializing in the development of..

Day One Biopharmaceuticals, Inc (DAWN): Investor Outlook Highlights 78% Upside Potential and Strong Buy Ratings

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a dynamic player in the biotechnology sector, has been capturing attention with its promising pipeline and significant upside potential. With a current market capitalization..

Semler Scientific, Inc. (SMLR) Stock Analysis: Uncovering a 258% Potential Upside in the Medical Devices Sector

For investors with a keen eye on the healthcare sector, Semler Scientific, Inc. (NASDAQ: SMLR) presents a compelling opportunity. Operating within the medical devices industry, Semler Scientific is making strides..

RxSight, Inc. (RXST) Stock Analysis: Exploring a 30% Potential Upside in the Medical Devices Sector

Investors exploring opportunities within the healthcare sector might find RxSight, Inc. (RXST) an intriguing candidate, especially given its potential upside of over 30% as indicated by recent analyst ratings. Despite..

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Nearly 96% Upside Potential Amidst Strong Analyst Confidence

Investors with an eye on the healthcare sector might find Cullinan Therapeutics, Inc. (NASDAQ: CGEM) a compelling opportunity, especially given its promising potential for nearly 96% upside. The biopharmaceutical company,..

Search

Funds

March 6, 2026

Search

Funds

March 6, 2026

FTSE 100

Funds